Cyclo(-RGDfK) TFA

CAS No. 500577-51-5

Cyclo(-RGDfK) TFA( —— )

Catalog No. M22892 CAS No. 500577-51-5

Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 61 In Stock
5MG 91 In Stock
10MG 151 In Stock
25MG 293 In Stock
50MG 492 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Cyclo(-RGDfK) TFA
  • Note
    Research use only, not for human use.
  • Brief Description
    Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).
  • Description
    Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    αVβ3 integrin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    500577-51-5
  • Formula Weight
    717.69
  • Molecular Formula
    C29H42F3N9O9
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:100 mg/mL (139.34 mM; Need ultrasonic); H2O:33.33 mg/mL (46.44 mM; Need ultrasonic)
  • SMILES
    C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCN=C(N)N)CCCCN)CC2=CC=CC=C2)CC(=O)O.C(=O)(C(F)(F)F)O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.
molnova catalog
related products
  • Fibronectin CS1 Pept...

    he connecting segment 1 (CS-1) is a cell attachment domain located in the type III homology connecting segment (IIICS) of fibronectin. CS1 peptide of fibronectin, which lacks the Arg-Gly-Asp-containing domain, actively inhibits tumor metastases in spontaneous and experimental metastasis models. The use of Fibronectin CS1 Peptide might offer a promising therapeutic approach for combating and preventing cancer metastasis.

  • Volociximab

    Volociximab (M200) is an IgG4 monoclonal antibody targeting the α5β1 integrin , with antiangiogenic, antitumor and anticancer activity, inhibits the growth of rabbit VX2 tumors and is used to study solid tumors.

  • Natalizumab

    Natalizumab used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.